The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | L | Antineoplastic and immunomodulating agents | |
| 2 | L04 | Immunosuppressants | |
| 3 | L04A | Immunosuppressants | |
| 4 | L04AA | Selective immunosuppressants | |
| 5 | L04AA04 | Antithymocyte immunoglobulin (rabbit) |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| PAREN - Parenteral | 0.1 g |
| Active Ingredient | Description | |
|---|---|---|
| Antithymocyte immunoglobulin |
Antithymocyte immunoglobulin is a selective immunosuppressive agent mostly acting on T lymphocytes. Antithymocyte immunoglobulin is used for the prevention and treatment of graft rejection after solid organ transplantation, usually in combination with other immunosuppressive drugs. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| GRAFALON Concentrate for solution for infusion | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
| THYMOGLOBULINE Powder for solution for infusion | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
